GLAXOSMITHKLINE has
confirmed an offer from Aspen
Pharmacare for the acquisition
of a number of brands and a
manufacturing facility in France.
The proposed deal includes the
transfer of thrombosis brands
Arixtra (fondaparinux) and
Fraxiparine (nadroparin) to Aspen
(excluding in China, India and
Pakistan), along with the factory in
Notre-Dame de Bondeville.
A period of exclusivity has been
agreed between Aspen and GSK,
which said it would respond to the
offer “subject to consultation with
employees”.
Financial terms are confidential
at present, with GSK saying the
proposed transaction is in line with
its “strategy of focusing on products
with the most growth potential and
the delivery of its pipeline”.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jun 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jun 13
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.